The results of this study also complement the main findings of the STEP-HFpEF programme, which demonstrated that semaglutide results in disease modification (early and sustained lowering of NT-proBNP; and fewer HF events) by showing that semaglutide leads to clinically relevant and statistically significant reduction in daily loop diuretic dose over time. The gene discussed is NPPB; the disease is hydrops fetalis.